Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

Completed · Phase 1

Conditions studied: Acute Respiratory Distress Syndrome

In brief

This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.

Key facts

Study ID

NCT01775774

Run by

Michael A. Matthay

People needed

9

Starts

2013-07-01

Expected to finish

2015-02-01

Last updated by the study team

2017-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:
• Acute onset (defined below) of:
• A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP)
• Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph
• No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.
• In addition to meeting inclusion criteria, enrollment must occur within 96-hours of first meeting ARDS criteria per the Berlin definition of ARDS.

You may not qualify if…

• Age less than 18 years
• Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of ARDS
• Pregnant or breast-feeding
• Prisoner
• Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last 2 years
• Any other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%
• Moderate to severe liver failure (Childs-Pugh Score > 12)
• Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen
• Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
• Major trauma in the prior 5 days
• Lung transplant patient
• No consent/inability to obtain consent
• Moribund patient not expected to survive 24 hours
• WHO Class III or IV pulmonary hypertension
• Documented deep venous thrombosis or pulmonary embolism within past 3 months
• No arterial line/no intent to place an arterial line
• No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol
• Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)

Where it is running

• University of California San Francisco Medical Center — San Francisco, California, United States
• Stanford University Medical Center — Stanford, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.